TheraRadar
← Back
Data updated: Jun 28, 2026

LABS DELBERT

Specialty

LABS DELBERT is a specialty pharmaceutical company focused on Infectious Disease, Respiratory, Dermatology.

1986
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

LABS DELBERT's Key Drugs

LABS DELBERT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LABS DELBERT's Recent FDA Approvals

New NDA/BLA approvals for LABS DELBERT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LABS DELBERT's Therapeutic Areas

LABS DELBERT's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
1 drugs
Respiratory 33%
1 drugs
Dermatology 33%
1 drugs

LABS DELBERT's Top Competitors

LABS DELBERT's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, PHARMACIA AND UPJOHN, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LABS DELBERT Pipeline Snapshot

Active clinical trials for LABS DELBERT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling